Diabetes as a risk factor for pneumococcal disease and severe related outcomes and efficacy/effectiveness of vaccination in diabetic population. Results from meta-analysis of observational studies.
Diabetes mellitus
Pneumococcal disease
Pneumococcal vaccination
Journal
Acta diabetologica
ISSN: 1432-5233
Titre abrégé: Acta Diabetol
Pays: Germany
ID NLM: 9200299
Informations de publication
Date de publication:
29 Apr 2024
29 Apr 2024
Historique:
received:
30
10
2023
accepted:
23
03
2024
medline:
30
4
2024
pubmed:
30
4
2024
entrez:
29
4
2024
Statut:
aheadofprint
Résumé
To collect all available evidence on the effect of diabetes mellitus (DM) as a risk factor for pneumococcal disease incidence and related complications, and on the efficacy/effectiveness of vaccines in patients with DM. Two distinct systematic searches on MEDLINE, Cochrane, ClinicalTrials.gov and EMBASE databases were performed, one for each meta-analysis, collecting all observational (cohort and case-control) studies and randomized clinical trials performed on humans up to June 1st, 2023. We retrieved 36 observational studies comparing risk for pneumococcal disease and related complications in people with or without DM, and 11 studies (1 randomized clinical trial and 10 observational studies) assessing conjugated and polysaccaridic vaccines efficacy/effectiveness on preventing such outcomes. People with DM were at higher risk for Invasive Pneumococcal Disease (unadjusted OR 2.42 [2.00; 2.92]); Case-Fatality Rate (unadjusted OR 1.61 [1.25; 2.07], Pneumococcal pneumonia (unadjusted OR 2.98 [2.76; 3.22), and Intensive care unit admission for pneumococcal disease (unadjusted OR 2.09 [1.20; 3.66]). In diabetic individuals vaccinated with conjugated vaccine, incidence of pneumonia specific for vaccine type in a clinical trial (OR 0.237 [0.008; 0.704]), and hospitalization for overall pneumonia during the year following the polysaccharide vaccination in observational studies (unadjusted OR 0.63 [0.45-0.89]) were significantly lower in comparison with unvaccinated DM subjects, with no significant differences for other outcomes. People with diabetes mellitus are at higher risk for less favourable course of pneumococcal disease and should be therefore targeted in vaccination campaigns; more evidence needs to be collected on vaccination outcomes in people with diabetes.
Identifiants
pubmed: 38684540
doi: 10.1007/s00592-024-02282-5
pii: 10.1007/s00592-024-02282-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Jain S, Self WH, Wunderink RG et al (2015) Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 373:415–427. https://doi.org/10.1056/NEJMoa1500245
doi: 10.1056/NEJMoa1500245
pubmed: 26172429
pmcid: 4728150
Kyaw MH, Rose CE Jr, Fry AM et al (2005) The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis 192:377–386. https://doi.org/10.1086/431521
doi: 10.1086/431521
pubmed: 15995950
Smith SA, Poland GA (2000) Use of influenza and pneumococcal vaccines in people with diabetes. Diabetes Care 23:95–108. https://doi.org/10.2337/diacare.23.1.95
doi: 10.2337/diacare.23.1.95
pubmed: 10857977
Farrar JL, Childs L, Ouattara M et al (2023) Systematic review and meta-analysis of the efficacy and effectiveness of pneumococcal vaccines in adults. Pathogens 12:732. https://doi.org/10.3390/pathogens12050732
doi: 10.3390/pathogens12050732
pubmed: 37242402
pmcid: 10222197
Huijts SM, Van Werkhoven CH, Bolkenbaas M, Grobbee DE, Bonten MJM (2017) Post-hoc analysis of a randomized controlled trial: diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly. Vaccine 35:4444–4449. https://doi.org/10.1016/j.vaccine.2017.01.071
doi: 10.1016/j.vaccine.2017.01.071
pubmed: 28410813
Kobayashi M, Farrar JL, Gierke R et al (2022) Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. adults: updated recommendations of the advisory committee on immunization practices—United States, 2022. MMWR Morb Mortal Wkly Rep 71:109–117. https://doi.org/10.15585/mmwr.mm7104a1
doi: 10.15585/mmwr.mm7104a1
pubmed: 35085226
pmcid: 9351524
European Medicines Agency EU. Apexxnar n.d.
European Medicines Agency EU. Vaxneuvance n.d.
World Health Organization. Pneumococcal vaccines: WHO position paper on their use in community outbreak settings n.d.
European Centre for Disease Prevention and Control EU. Vaccine scheduler-pneumococcal disease: recommended vaccinations n.d.
Van Deursen AMM, Van Houten MA, Webber C et al (2018) The impact of the 13-valent pneumococcal conjugate vaccine on pneumococcal carriage in the community acquired pneumonia immunization trial in adults (CAPiTA) study. Clin Infect Dis 67:42–49. https://doi.org/10.1093/cid/ciy009
doi: 10.1093/cid/ciy009
pubmed: 29324986
Janssens A, Vaes B, Abels C et al (2023) Pneumococcal vaccination coverage and adherence to recommended dosing schedules in adults: a repeated cross-sectional study of the INTEGO morbidity registry. BMC Public Health 23:1104. https://doi.org/10.1186/s12889-023-15939-7
doi: 10.1186/s12889-023-15939-7
pubmed: 37286969
pmcid: 10245355
PROSPERO DATABASE. https://www.crd.york.ac.uk/prospero ) n.d.
Review Manager (RevMan) (2020) [Computer program]. Version 5.4. The Cochrane Collaboration. n.d.
Comprehensive Meta-analysis, Biostat 14 North Dean Street Englewood, NJ 07631 USA n.d.
Shea KM, Edelsberg J, Weycker D, Farkouh RA, Strutton DR, Pelton SI (2014) Rates of pneumococcal disease in adults with chronic medical conditions. Open Forum Infect Dis 1:ofu024. https://doi.org/10.1093/ofid/ofu024
doi: 10.1093/ofid/ofu024
pubmed: 25734097
pmcid: 4324183
Van Hoek AJ, Andrews N, Waight PA et al (2012) The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 65:17–24. https://doi.org/10.1016/j.jinf.2012.02.017
doi: 10.1016/j.jinf.2012.02.017
pubmed: 22394683
Austrian R (1964) Pneumococcal bacteremia with especial reference to bacteremic pneumococcal pneumonia. Ann Intern Med 60:759. https://doi.org/10.7326/0003-4819-60-5-759
doi: 10.7326/0003-4819-60-5-759
pubmed: 14156606
Aydin MA, Janapatla RP, Chen C-L, Li H-C, Su L-H, Chiu C-H (2023) Microbiological and clinical characteristics of Streptococcus pneumoniae serotype 3 infection and risk factors for severe outcome: a multicenter observational study. J Microbiol Immunol Infect 56:598–604. https://doi.org/10.1016/j.jmii.2023.01.013
doi: 10.1016/j.jmii.2023.01.013
pubmed: 36774315
Baxter R, Yee A, Aukes L et al (2016) Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults. Vaccine 34:4293–4297. https://doi.org/10.1016/j.vaccine.2016.07.003
doi: 10.1016/j.vaccine.2016.07.003
pubmed: 27396493
Cardinal-Fernández P, García Gabarrot G, Echeverria P, Zum G, Hurtado J, Rieppi G (2013) Clinical and microbiological aspects of acute community-acquired pneumonia due to Streptococcus pneumoniae. Revista Clínica Española (English Edition) 213:88–96. https://doi.org/10.1016/j.rceng.2012.12.001
doi: 10.1016/j.rceng.2012.12.001
Di Yacovo S, Garcia-Vidal C, Viasus D et al (2013) Clinical features, etiology, and outcomes of community-acquired pneumonia in patients with diabetes mellitus. Medicine 92:42–50. https://doi.org/10.1097/MD.0b013e31827f602a
doi: 10.1097/MD.0b013e31827f602a
pubmed: 23263718
pmcid: 5370750
Fedson DS (1983) Previous hospital care and pneumococcal bacteremia: importance for pneumococcal immunization. Arch Intern Med 143:885. https://doi.org/10.1001/archinte.1983.00350050039008
doi: 10.1001/archinte.1983.00350050039008
pubmed: 6679231
Feikin D, Schuchat A, Jorgensen JH (2000) Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health 90:223–229. https://doi.org/10.2105/AJPH.90.2.223
doi: 10.2105/AJPH.90.2.223
pubmed: 10667183
pmcid: 1446155
Flory JH, Joffe M, Fishman NO, Edelstein PH, Metlay JP (2009) Socioeconomic risk factors for bacteraemic pneumococcal pneumonia in adults. Epidemiol Infect 137:717–726. https://doi.org/10.1017/S0950268808001489
doi: 10.1017/S0950268808001489
pubmed: 18925988
Fukuda H, Onizuka H, Nishimura N, Kiyohara K (2022) Risk factors for pneumococcal disease in persons with chronic medical conditions: results from the LIFE study. Int J Infect Dis 116:216–222. https://doi.org/10.1016/j.ijid.2021.12.365
doi: 10.1016/j.ijid.2021.12.365
pubmed: 34986403
Garrouste-Orgeas M, Azoulay E, Ruckly S et al (2018) Diabetes was the only comorbid condition associated with mortality of invasive pneumococcal infection in ICU patients: a multicenter observational study from the Outcomerea research group. Infection 46:669–677. https://doi.org/10.1007/s15010-018-1169-6
doi: 10.1007/s15010-018-1169-6
pubmed: 29974388
Gil-Prieto R, Pascual-Garcia R, Walter S, Álvaro-Meca A, Gil-De-Miguel Á (2016) Risk of hospitalization due to pneumococcal disease in adults in Spain. The CORIENNE study. Hum Vaccines Immunother. https://doi.org/10.1080/21645515.2016.1143577
doi: 10.1080/21645515.2016.1143577
Inghammar M, Engström G, Kahlmeter G, Ljungberg B, Löfdahl C-G, Egesten A (2013) Invasive pneumococcal disease in patients with an underlying pulmonary disorder. Clin Microbiol Infect 19:1148–1154. https://doi.org/10.1111/1469-0691.12182
doi: 10.1111/1469-0691.12182
pubmed: 23464817
Ishiguro T, Kagiyama N, Uozumi R et al (2017) Clinical characteristics of influenza-associated pneumonia of adults: clinical features and factors contributing to severity and mortality. Yale J Biol Med 90:165–181
pubmed: 28656006
pmcid: 5482296
Jacups SP, Cheng A (2011) The epidemiology of community acquired bacteremic pneumonia, due to Streptococcus pneumoniae, in the top end of the Northern Territory, Australia—over 22 years. Vaccine 29:5386–5392. https://doi.org/10.1016/j.vaccine.2011.05.082
doi: 10.1016/j.vaccine.2011.05.082
pubmed: 21651943
Klemets P, Lyytikainen O, Ruutu P et al (2010) Risk of invasive pneumococcal infections among working age adults with asthma. Thorax 65:698–702. https://doi.org/10.1136/thx.2009.132670
doi: 10.1136/thx.2009.132670
pubmed: 20685743
Kornum JB, Thomsen RW, Riis A, Lervang H-H, Schønheyder HC, Sørensen HT (2007) Type 2 diabetes and pneumonia outcomes. Diabetes Care 30:2251–2257. https://doi.org/10.2337/dc06-2417
doi: 10.2337/dc06-2417
pubmed: 17595354
Kwak BO, Choung JT, Park YM (2015) The association between asthma and invasive pneumococcal disease: a nationwide study in Korea. J Korean Med Sci 30:60. https://doi.org/10.3346/jkms.2015.30.1.60
doi: 10.3346/jkms.2015.30.1.60
pubmed: 25552884
Leelarasamee A, Dhiraputra C, Hunnangkul S (1999) Severe pneumococcal infection at a Thai hospital. Int J Infect Dis 3:147–152. https://doi.org/10.1016/S1201-9712(99)90036-X
doi: 10.1016/S1201-9712(99)90036-X
pubmed: 10460926
Lin Y, Kuo H, Wu S, Nong B (2019) Identifying clinical factors associated with invasive pneumococcal disease in Taiwan. Kaohsiung J of Med Scie 35:379–381. https://doi.org/10.1002/kjm2.12041
doi: 10.1002/kjm2.12041
López-de-Andrés A, De Miguel-Díez J, Jiménez-Trujillo I et al (2017) Hospitalisation with community-acquired pneumonia among patients with type 2 diabetes: an observational population-based study in Spain from 2004 to 2013. BMJ Open 7:e013097. https://doi.org/10.1136/bmjopen-2016-013097
doi: 10.1136/bmjopen-2016-013097
pubmed: 28057653
pmcid: 5223662
Marrie TJ, Tyrrell GJ, Garg S, Vanderkooi OG (2011) Factors predicting mortality in invasive pneumococcal disease in adults in Alberta. Medicine 90:171–179. https://doi.org/10.1097/MD.0b013e31821a5a76
doi: 10.1097/MD.0b013e31821a5a76
pubmed: 21512414
Morrill HJ, Caffrey AR, Noh E, LaPlante KL (2014) Epidemiology of pneumococcal disease in a national cohort of older adults. Infect Dis Ther 3:19–33. https://doi.org/10.1007/s40121-014-0025-y
doi: 10.1007/s40121-014-0025-y
pubmed: 25134809
pmcid: 4108120
Mufson MA, Kruss DM, Wasil RE, Metzger WI (1974) Capsular types and outcome of bacteremic pneumococcal disease in the antibiotic era. Arch Intern Med 134:505–510
doi: 10.1001/archinte.1974.00320210115016
pubmed: 4152800
Seminog OO, Goldacre MJ (2013) Risk of pneumonia and pneumococcal disease in people hospitalized with diabetes mellitus: English record-linkage studies. Diabet Med 30:1412–1419. https://doi.org/10.1111/dme.12260
doi: 10.1111/dme.12260
pubmed: 23796064
Vila-Corcoles A, Aguirre-Chavarria C, Ochoa-Gondar O et al (2015) Influence of chronic illnesses and underlying risk conditions on the incidence of pneumococcal pneumonia in older adults. Infection 43:699–706. https://doi.org/10.1007/s15010-015-0801-y
doi: 10.1007/s15010-015-0801-y
pubmed: 26037386
Wagenvoort GHJ, Knol MJ, De Melker HE et al (2016) Risk and outcomes of invasive pneumococcal disease in adults with underlying conditions in the post-PCV7 era. Neth Vaccin 34:334–340. https://doi.org/10.1016/j.vaccine.2015.11.048
doi: 10.1016/j.vaccine.2015.11.048
Watt JP, O’Brien KL, Benin AL et al (2007) Risk factors for invasive pneumococcal disease among Navajo adults. Am J Epidemiol 166:1080–1087. https://doi.org/10.1093/aje/kwm178
doi: 10.1093/aje/kwm178
pubmed: 17693393
Watanakunakorn C, Greifenstein A, Stroh K et al (1993) Pneumococcal bacteremia in three community teaching hospitals from 1980 to 1989. Chest 103:1152–1156. https://doi.org/10.1378/chest.103.4.1152
doi: 10.1378/chest.103.4.1152
pubmed: 8131456
Watanakunakorn C, Bailey TA (1997) Adult bacteremic pneumococcal pneumonia in a community teaching hospital, 1992–1996. A detailed analysis of 108 cases. Arch Intern Med 157:1965–1971
doi: 10.1001/archinte.1997.00440380069007
pubmed: 9308508
Willis R, Heslop O, Bodonaik N, Thame M, Smikle M (2019) Morbidity, mortality and antimicrobial resistance of pneumococcal infections in the Jamaican paediatric and adult populations. HAB 27:155–160. https://doi.org/10.3233/HAB-180361
doi: 10.3233/HAB-180361
Thomsen RW, Hundborg HH, Lervang H-H, Johnsen SP, Sørensen HT, Schønheyder HC (2004) Diabetes and outcome of community-acquired pneumococcal bacteremia. Diabetes Care 27:70–76. https://doi.org/10.2337/diacare.27.1.70
doi: 10.2337/diacare.27.1.70
pubmed: 14693969
Lipsky BA, Boyko EJ, Inui TS, Koepsell TD (1986) Risk factors for acquiring pneumococcal infections. Arch Intern Med 146:2179–2185
doi: 10.1001/archinte.1986.00360230105016
pubmed: 3778047
Benin AL, O’Brien KL, Watt JP et al (2003) Effectiveness of the 23-valent polysaccharide vaccine against invasive pneumococcal disease in Navajo adults. J Infect Dis 188:81–89. https://doi.org/10.1086/375782
doi: 10.1086/375782
pubmed: 12825175
McDonald HI, Thomas SL, Millett ERC, Quint J, Nitsch D (2017) Do influenza and pneumococcal vaccines prevent community-acquired respiratory infections among older people with diabetes and does this vary by chronic kidney disease? A cohort study using electronic health records. BMJ Open Diab Res Care 5:e000332. https://doi.org/10.1136/bmjdrc-2016-000332
doi: 10.1136/bmjdrc-2016-000332
pubmed: 28461899
pmcid: 5387965
Butler JC, Breiman RF, Campbell JF, Lipman HB, Broome CV, Facklam RR (1993) Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 270:1826–1831
doi: 10.1001/jama.1993.03510150060030
pubmed: 8411526
Hsiao A, Hansen J, Timbol J et al (2022) Incidence and estimated vaccine effectiveness against hospitalizations for all-cause pneumonia among older US adults who were vaccinated and not vaccinated with 13-valent pneumococcal conjugate vaccine. JAMA Netw Open 5:e221111. https://doi.org/10.1001/jamanetworkopen.2022.1111
doi: 10.1001/jamanetworkopen.2022.1111
pubmed: 35302634
pmcid: 8933738
Davis TME, Kauhanen J, Davis WA (2017) Pneumococcal vaccination and incident hospitalisation for pneumonia in type 2 diabetes: the Fremantle Diabetes Study Phase II. Intern Med J 47:1206–1210. https://doi.org/10.1111/imj.13569
doi: 10.1111/imj.13569
pubmed: 28994256
Fisman DN, Abrutyn E, Spaude KA, Kim A, Kirchner C, Daley J (2006) Prior pneumococcal vaccination is associated with reduced death, complications, and length of stay among hospitalized adults with community-acquired pneumonia. Clin Infect Dis 42:1093–1101. https://doi.org/10.1086/501354
doi: 10.1086/501354
pubmed: 16575726
Kuo C-S, Lu C-W, Chang Y-K et al (2016) Effectiveness of 23-valent pneumococcal polysaccharide vaccine on diabetic elderly. Medicine 95:e4064. https://doi.org/10.1097/MD.0000000000004064
doi: 10.1097/MD.0000000000004064
pubmed: 27368047
pmcid: 4937961
Skull SA, Andrews RM, Byrnes GB et al (2007) Prevention of community-acquired pneumonia among a cohort of hospitalized elderly: benefit due to influenza and pneumococcal vaccination not demonstrated. Vaccine 25:4631–4640. https://doi.org/10.1016/j.vaccine.2007.03.015
doi: 10.1016/j.vaccine.2007.03.015
pubmed: 17478015
Vila-Corcoles A, Hospital I, Ochoa-Gondar O et al (2020) Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: the EPIVAC cohort study, 2015–2016. Vaccine 38:1170–1180. https://doi.org/10.1016/j.vaccine.2019.11.012
doi: 10.1016/j.vaccine.2019.11.012
pubmed: 31759735
Wagner C, Popp W, Posch M, Vlasich C, Rosenberger-Spitzy A (2003) Impact of pneumococcal vaccination on morbidity and mortality of geriatric patients: a case-controlled study. Gerontology 49:246–250. https://doi.org/10.1159/000070405
doi: 10.1159/000070405
pubmed: 12792160
Torres A, Blasi F, Dartois N, Akova M (2015) Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease: Table 1. Thorax 70:984–989. https://doi.org/10.1136/thoraxjnl-2015-206780
doi: 10.1136/thoraxjnl-2015-206780
pubmed: 26219979
Casqueiro J, Casqueiro J, Alves C (2012) Infections in patients with diabetes mellitus: a review of pathogenesis. Indian J Endocr Metab 16:27. https://doi.org/10.4103/2230-8210.94253
doi: 10.4103/2230-8210.94253
Shapiro ED, Berg AT, Austrian R et al (1991) The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 325:1453–1460. https://doi.org/10.1056/NEJM199111213252101
doi: 10.1056/NEJM199111213252101
pubmed: 1944423
Verstraeten T, Fletcher MA, Suaya JA et al (2020) Diabetes mellitus as a vaccine-effect modifier: a review. Expert Rev Vaccin 19:445–453. https://doi.org/10.1080/14760584.2020.1760098
doi: 10.1080/14760584.2020.1760098
EpiCentro—Epidemiology for public health. Epidemiological data n.d.
Rueda AM, Ormond M, Gore M et al (2010) Hyperglycemia in diabetics and non-diabetics: effect on the risk for and severity of pneumococcal pneumonia. J Infect 60(2):99–105. https://doi.org/10.1016/j.jinf.2009.12.003
doi: 10.1016/j.jinf.2009.12.003
pubmed: 20005251